Clinical Trial

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

Study acronym: EXOMIC
Completed
View on ClinicalTrials.gov →
Summary
Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking. The EXOMIC study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to detect occult metastasis preoperatively in patients with resectable ICC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-03; most recent amendment 2026-03-11.
Status change: Recruiting → Completed 2026-03-11
Trial Details
NCT Number NCT07224737
Lead Sponsor City of Hope Medical Center
Conditions Intrahepatic Cholangiocarcinoma (Icc)
Enrollment 230 participants
Start Date 2024-06-21
Primary Completion 2026-01-18 (estimated)
Study Completion 2026-02-18 (estimated)
Updated on ClinicalTrials.gov 2026-03-13